Abstract
A newly developed quinolone antimicrobial drug, balofloxacin, was used in 27 patients with infectious diseases in the field of urology, and the following results were obtained:
1) The drug efficacy was rated as excellent in 12 patients, effective in 4 and ineffective in 5, in the 21 out of 25 patients with complex urinary tract infection in whom the results were consistent with the Drug Evaluation Criteria proposed by the Japanese Urinary Tract Infection Committee. The efficacy rate was 76.2%. The eradication rate was 86.2%(25/29) of the 16 isolated species.
2) The clinical efficacy was rated as effective in both a patient with urethritis and a patient with acute prostatitis, by physician's evaluation.
3) Nausea was observed in one patient and eruption in another, as side effects. Elevated monocytes and total bilirubin were observed in one patient each, as abnormal changes in clinical laboratory test values.
